Hormone therapy in breast cancer: The end of tamoxifen?;L'hormonothérapie du cancer du sein: La fin du tamoxifène?

Bulletin du Cancer

Volumn 92, Issue 2, 2005, Pages 142-150

  Delozier, Thierry ^a  

^a CENTRE FRANÇOIS BACLESSE   (France)

Author keywords

Anastrozole; Breast neoplasm; Exemestane; Goserelin; Letrozole; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; BUSERELIN; EXEMESTANE; GESTAGEN; GONADORELIN AGONIST; GOSERELIN; LETROZOLE; MEDROXYPROGESTERONE; TAMOXIFEN; TRIPTORELIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL;

BREAST CANCER; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG RESPONSE; DRUG TOLERANCE; HUMAN; MENOPAUSE; META ANALYSIS; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; DRUG EFFECT; FEMALE; METABOLISM; OVARY;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTRADIOL; FEMALE; HUMANS; MENOPAUSE; OVARY; PREMENOPAUSE; TAMOXIFEN;

EID: 14544293557     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Leung BS, Fletcher WS, Lindell TD, Wood DC, Krippaechne WW. Predictability of response to endocrine ablation in advanced breast carcinoma. A correlation to estrogen receptor and steroid sulfurylation. Arch Surg 1973; 106: 515-9.
2. Leung BS, Fletcher WS, Krippaehne WW. Estrogen receptor: a valid test for selection of breast cancer patients for endocrine ablation. Surg Forum 1973; 24: 125-7.
3. Namer M. Current status of hormonotherapy of metastatic cancer of the breast. Bull Cancer 1989; 76: 65-73.
4. Ribeiro G, Swindell R. The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma-7-yr results. Eur J Cancer Clin Oncol 1985; 21: 897-900.
5. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1983; 5: 257-61.
6. Delozier T, Julien JP, Juret P, Veyret C, Couette JE, Graic Y, et al. Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial. Breast Cancer Res Treat 1986; 7: 105-9.
7. Davidson NE. Ovarian ablation as treatment for young women with breast cancer. J Natl Cancer Inst Monogr 1994: 95-9.
8. Boccardo F, Rubagotti A, Perrorta A, Amoroso D, Balestrero M, De Matteis A, et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol 1994; 5: 337-42.
9. Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahmann DL, et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 1986;4: 178-85.
10. Bajetta E, Zilembo N, Buzzoni R, Celio L, Zampino MG, Colleoni M, et al. Goserelin in premenopausal advanced breast cancer: clinical and endocrine evaluation of responsive patients. Oncology 1994; 51: 262-9.
11. Bianco AR, Rosso R, Calabresi F, Fiorentino M, Lopez M, Sismondi PG, et al. LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study). Eur J Gynaecol Oncol 1991; 12 429-37.
12. Blamey RW, Jonat W, Kaufmann M, Bianco AR, Namer M. Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer 1992; 28A: 810-4.
13. Brambilla C, Escobedo A, Artioli R, Lechuga MJ, Motta M, Bonadonna G. Medical castration with zoladex: a conservative approach to premenopausal breast cancer. Tumori 1991; 77: 145-50.
14. Dixon AR, Robertson JF, Jackson L, Nicholson RI, Walker KJ, Blamey RW Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival. Br J Cancer 1990; 62: 868-70.
15. Kaufmann M, Jonat W, Schachner-Wunschmann E, Bastert G, Maass H. The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer: a 5-year experience and further endocrine therapies. Cooperative German Zoladex Study Group. Onkologie 1991; 14: 22-8.
16. Klijn JG, Beex LV, Mauriac L, Van Zijl JA, Veyret C, Wildiers J, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 2000; 92: 903-11.
17. Williams MR, Walker KJ, Turkes A, Blamey RW, Nicholson RI. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 1986; 53: 629-36.
18. Garcia-Giralt E, Beuzeboc P, Dieras V, Dorval T, Jouve M, Livartowski A, et al. P. Phase II trial of decapeptyl (D-TRP-6), a potent luteinizing hormone-releasing hormone analogue in untreated advanced breast cancer. Am J Clin Oncol 1996; 19: 455-8.
19. Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 1998; 16: 994-9.
20. Robert NJ, Dalton WS, Osborne CK, Abeloff M. Therapy in premenopausal women with advanced, œstrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex. Horm Res 1989; 32(Suppl 1): 221-2.
21. Tyrrell C. A multi-centre randomised study to compare the effects of ovarian ablation with Zoladex depot in pre- and perimenopausal patients with advanced breast cancer. Horm Res 1989; 32(Suppl 1): 218-20.
22. Crump M, Sawka CA, DeBoer G, Buchanan RB, Ingle JN, Forbes J, et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 1997; 44: 201-10.
23. Sawka CA, Pritchard KI, Shelley W, DeBoer G, Paterson AH, Meakin JW, et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA. 1. Breast Cancer Res Treat 1997; 44: 211-5.
24. Crump M, Sawka CA, DeBoer G, Buchanan RB, Ingle JN, Forbes J, et al. An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 1997; 44: 201-10.
25. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001; 19: 343-53.
26. Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004; 90: 590-4.
27. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996; 14: 2000-11.
28. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-61.
29. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18: 1399-411.
30. Longer time to tumor progression with exemestane vs tamoxifen in advanced breast cancer. Oncology (Huntingt) 2000; 14: 1291-4.
31. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, Von Euler M, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92: 2247-58.
32. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-606.
33. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. A phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101-9.
34. Mauriac L, Pippen JE, Quaresma Albano J, Gertler SZ, Osborne CK. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003; 39: 1228-33.
35. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004; 22: 1605-13.
36. Ovarian ablation for early breast cancer. Early Breast Cancer Trialists' Collaborative Group. Cochrane Database Syst Rev 2000; CD000485.
37. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 1543-9.
38. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group. J Natl Cancer Inst 1996; 88: 1834-9.
39. Delozier T, Spielmann M, Mace-Lesec'h J, Janvier M, Hill C, Asselain B, et al. Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Federation Nationale des Centres de Lutte Contre le Cancer Breast Group. J Clin Oncol 2000; 18: 3507-12.
40. Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 9: 286-94.
41. Barakar RR, Gilewski TA, Almadrones L, Saigo PE, Venkatraman E, Hudis C, et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 2000; 18: 3459-63.
42. Chen P, Yang CC, Chen YJ, Wang PH. Tamoxifen-induced endometrial cancer. Eur J Gynaecol Oncol 2003; 24: 135-7.
43. ATAC group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-9.
44. Coombes RC, Hall E, Gibson LJ, Patidaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-92.
45. Gross PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-802.
46. Spano JP, Kayat D, Delozier T. Place des inhibiteurs de l'aromarase en situation adjuvante. Bull Cancer 2005 (in Press).
47. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Int 1996; 88: 1529-42.
48. Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996; 74: 297-9.
49. Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst 2001; 93: 456-62.
50. Earl H, Gray R, Kerr D, Lee M. The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom. Clin Oncol 1997; 9: 141-3.
51. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684-90.
52. Delozier T, Switsers O, Genot JY, Ollivier JM, Hery M, Namer M, et al. Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial. Bull Cancer 1997; 84: 25-30.